Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-Arm, Phase 1b Study to Assess Tumor-Treating Fields (TTF) in Combination With Durvalumab and Gemcitabine/Cisplatin (GemCis) as the First-Line Treatment of Unresectable Biliary Tract Cancers (BTC)

NCT06611345 is registered in ClinicalTrials.gov with Jiangsu Healthy Life Innovation Medical Technology Co., Ltd as lead sponsor.

NCT NCT06611345
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06611345 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-Arm, Phase 1b Study to Assess Tumor-Treating Fields (TTF) in Combination With Durvalumab and Gemcitabine/Cisplatin (GemCis) as the First-Line Treatment of Unresectable Biliary Tract Cancers (BTC)
Lead sponsor
Jiangsu Healthy Life Innovation Medical Technology Co., Ltd
Phase
Not applicable
Overall status
Recruiting
Start date
October 21, 2024
Completion date
March 30, 2027
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

biliary tract cancers (btc)